SAN DIEGO and SUZHOU, China, Dec 14 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company’s website at www.adagene.com.
http://mrem.bernama.com/viewsm.php?idm=41919
- Sharjah Hosts Global Investment Conference Focused On Sustainability, Resilience
- Feature: Jordan Safeguards Millions Of Migratory Birds Journeying Along Vital Flyway
- Egypt Announces New Oil, Gas Discoveries In Western Desert, Nile Delta
- Jordan Inaugurates Integrated Digital Hub
- Iraq Arrests Five Suspects Over Killing Of Parliamentary Candidate
- Paetongtarn Shinawatra Resigns As Pheu Thai Party Leader
- Türkiye Extends Troop Deployment In Iraq, Syria
- Sanae Takaichi Elected Japan PM, Unveils Cabinet Lineup
- Japan’s LDP, Japan Innovation Party Sign Coalition Agreement
- Iran Says Cooperation Deal With UN Nuclear Watchdog Void